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Background. Breastfeeding imparts beneﬁcial immune protection and nutrition to infants for healthy growth,
but it is also a route for human immunodeﬁciency virus (HIV) and human cytomegalovirus (HCMV) infection.
In previous studies, we showed that HCMV adversely affects infant development in Africa, particularly with
maternal HIV exposure. In this study, we analyzed infants risks for acquisition of HCMV infection from
breastfeeding and compared HIV-positive and HIV-negative mothers.
Methods. Two cohorts were studied in Zambia. (1) Two hundred sixty-one HIV-infected and HIV-uninfected
mothers were compared for HCMV deoxyribonucleic acid (DNA) loads and genotypes (glycoprotein gO) in
milk from birth to 4 months postpartum. (2) Maternally HIV-exposed and HIV-unexposed infants were
compared for HCMV infection risk factors. The second cohort of 460 infants, from a trial of micronutrient-
fortiﬁed complementary-food to breastfeeding, were studied between 6 and 18 months of age. Human
cytomegalovirus seroprevalence was assayed, and logistic regression was used to calculate risk factors for
HCMV infection, including maternal HIV exposure and breastfeeding duration.
Results. Human cytomegalovirus was detected in breast milk from 3 days to 4 months postpartum, with
signiﬁcantly raised levels in HIV-positive women and independent of genotype. In infants, HCMV antibody
seroprevalence was 83% by 18months age. Longer breastfeeding duration increased infection risk in maternally
HIV-unexposed (odds ratio [OR] = 2.69 for 18 months vs <12 months; 95% conﬁdence interval [CI], 0.84–
8.59; P = .03) and HIV-exposed infants (OR = 20.37 for >6 months vs never; 95% CI, 3.71–111.70; P < .001).
Conclusions. Prolonged breastfeeding, which is common in Africa, increased risk of HCMV infection in
infants. Both HIV-positive and HIV-negative women had extended milk HCMV secretion. Women who were
HIV-positive secreted higher HCMV levels, and for longer duration, with their children at increased infection
risk. Human cytomegalovirus control is required to maintain health beneﬁts of breastfeeding.
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Human cytomegalovirus (HCMV) is a cause of serious dis-
ease in infancy particularly with immunosuppression from
human immunodeﬁciency virus (HIV) [1]. Congenital
HCMV, acquired in utero, is the main infectious cause of
mental retardation and neurodevelopmental impairment
in neonates [1]. Postnatal infection, mainly via breast
milk, can cause severe morbidity in some preterm or low
birthweight babies [2–10]. Human immunodeﬁciency
virus and HCMV coinfected children have increased neu-
rological and respiratory disease, acquired immune deﬁ-
ciency syndrome (AIDS) progression, and death [11–13].
In sub-Saharan Africa where HIV is endemic, maternal
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HCMVplasma deoxyribonucleic acid (DNA)was linked to
increased mortality in both mother and child in Kenya
[14]. Human cytomegalovirus secretion in milk is asso-
ciated with infant HIV transmission in South Africa and
Malawi [15, 16]. In maternally HIV-exposed Zambian
children, who themselves remained HIV-negative, we
showed that HCMV was associated with lower infant
growth and psychomotor development [17]. In Zimbabwe,
HCMVmilk secretion was related to growth faltering in ma-
ternally HIV-exposed children [18]. West African children
infectedwithHCMValready express theHCMV “aged” im-
mune phenotype, present in older Europeans, which may
alter immune responses to infections and vaccines [19, 20].
Although maternal HIV exposure has been shown to in-
crease HCMV congenital infection prevalence (from 1%
to 4% [21–25]), the effects of maternal HIV on postnatal
HCMV transmission via breastfeeding, the predominant
route of infection, is unknown [26]. In women who are
HIV-positive, a correlation has been made among milk
HCMV loads, lower CD4 counts, reduced growth, and in-
fant transmission [18, 27]. However, because comparisons
have not been made to mothers who are HIV-negative, it is
not known whether maternal HIV causes greater HCMV
reactivation, load, or extended secretion in milk. In addi-
tion, the effects of breastfeeding duration, which varies
greatly in women who are HIV-positive, are unknown. In
Europe, breastfeeding of infants up to 3 months of age and
raised HCMV viral load in breast milk increased risks of
HCMV infection [3, 28]. In Africa, extended breastfeeding
into the second year of life is common practice. In order
to apply any intervention against HCMV, it is important
to determine infection risk factors and their timing in
HIV-positive versus HIV-negative women, especially in en-
demic regions of Africa where comorbidity is increased.
In this study, we examined breast milk directly for
HCMV DNA loads and genotypes. In addition, we exam-
ined the association of breastfeeding duration with HCMV
infant infection risks in Zambia, where maternal HIV ex-
posure is frequent. To our knowledge, there is no previous
research comparing the effects of maternal HIV status on
secretion and transmission of HCMV in breast milk. In
this study, we have compared both HIV-positive and
HIV-negative mothers in order to understand the effects
of breastfeeding practice and HIV on secretion and trans-
mission of HCMV.
METHODS
Ethical Approval
This study was approved by the ethics committees of both
the University of Zambia and the London School of
Hygiene and Tropical Medicine, University of London.
Study Population and Protocol
Studies were conducted at Chilenje clinic in Lusaka,
Zambia, in 2 cohorts: in the ﬁrst cohort, studies examined
extended HCMV secretion in breast milk; the second co-
hort focused on the physiological relevance in the longer
term. Both cohorts were recruited from a similar region
served by the clinic, many mothers participated in both co-
horts, and there were similar antiretroviral therapy (ART)
treatment protocols. At the time of the studies, local care
standards included single-dose of nevirapine for HIV-
positive mothers and their newborns. In the second, later
cohort, ART was available to mothers with CD4 count
<200 cells/μL, and towards the end of the study this was
changed to <350 cells/μL, in accordance with revised
National HIV treatment guidelines (Ministry of Health,
Zambia). Only a few mothers in the study were on ART.
Breastfeeding Cohort. The Breastfeeding and Postpartum
Health study investigated postpartum health among 387
(198 HIV negative, 189 HIV positive) women, from
2001 to 2003 [29]. Breastfeeding was a recruitment
criterion, and all women were breastfeeding exclusively
or predominantly. Milk samples were collected on 11
scheduled visits during the ﬁrst 16 postpartum weeks and
stored at −80°C. Two hundred sixty-one milk samples
(from 118 HIV-positive and 143 HIV-negative mothers),
collected at postpartum week 16, were available for our
study. For a subset of 40 women (20 HIV-negative and
20 HIV-positive), we also analyzed samples collected at 5
earlier time points: day 3, and weeks 2, 4, 9, and 12
postpartum. Maternal HIV serostatus was determined
antenatally using a serial testing algorithm, per local care
standards [28].
Infant Cohort. The Chilenje Infant Growth, Nutrition and
Infection Study (CIGNIS) was a randomized double-blind
controlled trial of micronutrient-fortiﬁed infant foods
(ISRCTN37460449; www.controlled-trials.com/mrct)
and was conducted from 2005 to 2009. Infants (n = 811)
were enrolled at 6 months of age and observed for 12
months [30]. Socio-demographic information was obtained
using a questionnaire at recruitment. At recruitment and
monthly, mothers were asked whether they were still
breastfeeding or when they stopped [31]. Infant venous
blood was collected in plain vacutainers, serum was
separated, and antibody was assayed for HIV and HCMV
at study completion (18 months age). Human immuno-
deﬁciency virus serostatus was determined using the local
Ministry of Health-approved serial testing algorithm as
described previously [17]. The ETI-CYTOK-G PLUS ELISA
Kit (DiaSorin) was used to test for HCMV immunoglobulin
(Ig)G, with standard curves plotted using control sera
provided and then used to interpolate each sample IgG
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titer; we considered HCMV IgG positive above a cutoff of
0.4 IU/mL.
Deoxyribonucleic Acid Extraction, Qualitative and
Quantitative Polymerase Chain Reaction
Deoxyribonucleic acid was extracted from 200 µL homog-
enized milk using the QIAamp DNA Mini kit (QIAGEN)
and eluted in 50 μL H2O. Human cytomegalovirus glyco-
protein gB gene was used for qualitative polymerase chain
reaction (PCR) screening and quantiﬁcation, human
GAPDH gene was used as internal control, and hypervar-
iable marker HCMV glycoprotein gO (gO) was used for
genotyping [17, 32, 33]. Human cytomegalovirus DNA
copy numbers were computed by TaqMan real-time
assay, performed in triplicate on the Applied Biosystems
7500 Fast Real-Time PCR System (Applied Biosystems
Inc.) [32]. Standard curves were generated from 10-fold se-
rial dilutions of plasmid-cloned ampliﬁcation products
(pGEM-T Easy Vector Systems, Promega), normalized
with an internationally certiﬁed clinical reference standard
(National Institute of Biological Standards and Control,
UK Medicines and Healthcare products Regulatory
Agency, Potters Bar, United Kingdom). Levels detected
below the sensitivity of the virus standard were recorded
at a value of half the limit of detection. Each quantitative
PCR (qPCR) reaction had 10 μL KAPA PROBE FAST
Universal qPCR Master Mix (Kapa Biosystems), 1 μL
probe (5 mM), 1 μL each of both forward and reverse
primer (10 mM), 0.4 μL ROX Low, 7 μL dH2O, and 5
μL template DNA. Cycling conditions were as follows:
95°C for 10 minutes, then 45 cycles of 95°C for 15 sec-
onds, and 60°C for 1 minute. All PCR assays included
both positive and negative controls (reagents and
water-only).
Genotyping
Human cytomegalovirus gO (UL74 gene) genotyping was
performed on a subset of 34 milk samples with sufﬁcient re-
maining volume. Based on translated amino acid sequences,
HCMV gO (UL74 gene) has 8 distinct genotypes: gO1a,
gO1b, gO1c, gO2a, gO2b, gO3, gO4, and gO5 [32, 33].
We used PCR-based genotyping with the gOup/gOlw prim-
ers, which detected all 8 gO genotypes. Nucleotide sequenc-
es were determined using Sanger methods [32, 33] and
compiled using ChromasPro software. Multiple alignments
used CLUSTAL and phylogenetic analysis via maximum-
likelihood methods in MEGA6 [34].
Statistical Analysis
Programs Prism (version 6; GraphPad Software, Inc.) and
SPSS (version 20.0; IBM Corp., Armonk, New York) were
utilized to analyze milk HCMV DNA data by Student’s t
test and Mann–Whitney U test with 2-tailed P values and
alpha = 0.05. Stata (version 11.1; StataCorp, College
Station, Texas) was used in analyses of the infant cohort
data, and odds ratios (ORs) and 95% conﬁdence intervals
(CIs) were obtained by logistic regression. We assessed asso-
ciations of breastfeeding duration with HCMV antibody at
18 months, in a multivariable model. Analyses were adjust-
ed for maternal education and socioeconomic status, as
main effect modiﬁers as described [17], and stratiﬁed byma-
ternal HIV status. To account for missing data, mainly from
limited infant serum sample volumes, we also imputed miss-
ing HCMV results using multiple imputations with chained
equations. The results imputed to account for missing data
were similar to the main analyses (data not shown).
RESULTS
Increased Loads and Duration of Human Cytomegalovirus
Milk Excretion in Human Immunodeﬁciency Virus-Positive
Women
Human cytomegalovirus DNA measurements were made
in 405 breast milk samples from 261 mothers at week 16
postpartum and a subset of 40 mothers at multiple time
points. In the longitudinal subset (Figure 1), all mothers
screened were HCMV positive by qualitative assay from
day 3, and the median HCMV DNA in day 3 milk (colos-
trum or transitional milk) was not signiﬁcantly different
in HIV-infected compared with HIV-uninfected mothers
(3.9 and 4.1 log10 copies/mL, respectively; P = .90).
Deoxyribonucleic acid lactia then increased in both groups,
reaching peak levels at week 4. In the HIV-negative
Figure 1. Human cytomegalovirus (HCMV) shedding kinetics in milk of human
immunodeﬁciency virus (HIV)-positive andHIV-negativewomen. Comparison of
milk HCMV deoxyribonucleic acid (DNA) kinetics between HIV-positive (black
lines) and negative women (gray lines) over the ﬁrst 16 postpartumweeks (n = 40,
20 in each group). Human cytomegalovirus DNA load, log copies/mL milk, in-
creased from comparable levels in the 2 groups from day 3 (week 1 [W1]) to
peak levels by week 4 (W4) postpartum. Sensitivity cut-off is indicated by the
lower dotted line. Milk DNA loads from HIV-positive women were raised com-
pared with HIV-negative women fromW4. Box plots show the median and inter-
quartile range using aMann–WhitneyU test, **P = .026 and ***P < .001 indicate
signiﬁcant differences from W4 and week 16 (W16), respectively.
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mothers, these loads declined gradually by week 16 to
below day 3 levels, whereas in HIV-infected mothers, the
DNA loads remained elevated. From week 4 to week 16,
the median DNA loads had sustained increases in
HIV-infected compared with the HIV-uninfected women
(P < .001 by week 16), with over a 10-fold difference at
peak levels recorded at week 4 (P = .026).
At week 16, HCMV was detected by the gB screening
assay in 83.9% (99 of 118) of milk from HIV-infected
women, versus 63.6% (91 of 143) in HIV-negative women
(P < .001). Human cytomegalovirus DNA loads were
quantiﬁed by real-time qPCR in 205 samples, all of
which contained sufﬁcient sample (with no demographic
differences). Of these, there was a signiﬁcantly higher pro-
portion of HIV-infected women with DNA levels above the
assay detection limit (88.0% [81 of 92] of HIV-infected
versus 59.3% [67 of 113] among HIV-uninfected;
P < .001). The mean DNA load was signiﬁcantly higher
in the HIV-infected group (7.9 × 104 copies/mL; 95% CI,
3.5 × 104 to 1.2 × 105) compared with the HIV-uninfected
group (1.1 × 104 copies/mL; 95% CI, 0.6 × 104 to 1.5 ×
104; P < .001) (Figure 2).
Human Cytomegalovirus GlycoproteinOGenotypes in Breast
Milk
Human cytomegalovirus gO (UL74 gene) genotyping was
performed in a subset of W4 (peak HCMV DNA loads)
and W16 (latest time point) milk samples. This included
all samples with sufﬁcient DNA and 7 samples paired at
both time points. On the basis of encoded amino acid se-
quences, all 8 HCMV gO distinct genotypes—gO1a,
gO1b, gO1c, gO2a, gO2b, gO3, gO4, and gO5 [32, 33]—
were detectable in the milk samples. These were predomi-
nantly genotypes 1a, 1b, and 5, as represented by reference
strains AD169, TR, andMerlin, respectively (Figure 3); ge-
notype prevalence differences in HIV-positive compared
with HIV-negative women did not reach signiﬁcance
(Supplementary Table S1). There was no evidence for high-
er viral load with any one genotype, although all appeared
Figure 2.Human cytomegalovirus (HCMV) deoxyribonucleic acid (DNA) loads
in week 16 milk samples, stratiﬁed by human immunodeﬁciency virus (HIV)
serostatus. Scatter plot showing HCMV DNA levels in all available milk sam-
ples, at week 16 (W16) (92 HIV-positive and 113HIV-negative). Human immu-
nodeﬁciency virus-positive women had a signiﬁcantly higher mean milk HCMV
DNA load, approaching 1 log higher, compared with their HIV-negative coun-
terparts. Furthermore, a higher proportion of milk samples from the
HIV-positive group remained with detectable HCMV at this late time point
(88.0% [81 of 92] vs 59.3% [67 of 113]; P < .001), with correspondingly de-
creased proportions below the limit of detection, indicated by the dashed line,
in the HIV-positive compared with HIV-negative group (12% [11 of 92] vs
40.7% [46 of 113]). Means were 7.9 × 104 and 1.1 × 104 copies/mL in
HIV-positive and HIV-negative women, respectively (P < .001, 2 sample, 2
tailed Student’s t test with 95% conﬁdence interval indicated by error bars),
with similar differences in the W16 values for the subset with the complete ki-
netics from Figure 1 as indicated by black circles, mean 8.2 × 104 and 0.5 × 104
copies/mL for HIV-positive compared with HIV-negative women.
Figure 3. Phylogenetic analyses glycoprotein O (gO) genotypes. Representatives
of genotype groups deﬁned here were analyzed in comparison to reference
strains, as described previously [32, 33]. Multiple alignments were performed
using CLUSTAL in MEGA6 [34], followed by phylogenetic constructions in-
ferred using the Maximum Likelihood method based on the JTT matrix-based
model. The analysis involved 39 amino acid sequences and 154 positions in the
ﬁnal dataset. Reference strains for gO genotypes are indicated. Bootstrapping
analyses indicate that major nodes are well supported.
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raised in milk samples from HIV-positive women com-
pared with HIV-negative women (Figure 4). Of the 7
paired samples, 3 had different genotypes detected at W4
and W16 (HIV-positive and HIV-negative).
Prevalence of Infant Human Cytomegalovirus Antibody at
18 Months of Age and Breastfeeding Duration
The effects of breastfeeding duration on infant HCMV
infection were compared between HIV-positive and HIV-
negative women in the CIGNIS infant cohort. Overall,
460 of 811 (57%) infant samples were available for
HCMV antibody testing at 18 months age. Most infants
were seropositive (384 of 460; 83%). As shown previously,
we found no effect of micronutrient fortiﬁcation (trial in-
tervention) on HCMV antibody at 18 months, either over-
all or by maternal HIV status, but the prevalence of
HCMV antibody signiﬁcantly increased with decreasing
maternal socioeconomic conditions or education and in-
creased with longer breastfeeding duration, which were
all measures adjusted in analyses of HCMV effects on
growth [17]. Breastfeeding duration differed markedly be-
tween HIV-infected and HIV-uninfected women in this co-
hort, as shown previously [31]. Of the HCMV study
subgroup analyzed here, only 3 HIV-negative women,
compared with 29 HIV-positive women, never breastfed;
and only an additional 6 HIV-negative women breastfed
for less than 6 months. Therefore, to further analyze this
result, we examined the effect of breastfeeding duration
on HCMV antibody stratiﬁed by maternal HIV status.
Among children of HIV-negative mothers, those who
were still breastfeeding at 18 months had nearly 3 times
the odds of HCMV antibody as those who had breastfed
for <12 months (OR = 2.69; 95% CI, 0.84–8.59; P = .03)
(Table 1). Even though it was a relatively small group
who were uninfected by 18 months age, the children of
HIV-positive mothers were now at signiﬁcantly greater
risk of early HCMV infection, as detected by antibody at
18 months, with prolonged breastfeeding (OR for breast-
feeding >6 months compared with no breastfeeding =
20.37; 95% CI, 3.71–111.70; P < .001) (Table 1).
DISCUSSION
The study shows widespread HCMV infections in Zambian
infants, from both HIV-positive and HIV-negative women.
Human cytomegalovirus seropositivity was 83% by 18
months age, which is both higher and earlier than in many
regions. Although similar to some other regions in Africa,
this population has the added effect of endemic HIV. In
Africa, the common practice of extended breastfeeding
was identiﬁed as a risk for HCMV infection, which was in-
creased for maternally HIV-exposed children. Furthermore,
HIV-positive women had strikingly higher loads of HCMV
secreted in their breast milk, with extended periods of raised
levels, compared with HIV-negative women. There was
some overlap so other factors may also inﬂuence secretion.
This is comparable to studies from East Africa that reported
high HCMV loads in HIV-infected women, although
comparisons to HIV-negative women were not made [27].
Our studies have now compared both HIV-positive and
HIV-negative mothers as well as considered breastfeeding
duration in this sub-Saharan African setting. Similar to
European and South East Asian surveys, our studies show
Figure 4. Genotype-independent increases in human cytomegalovirus (HCMV)
load in milk from human immunodeﬁciency virus (HIV)-positive women. Viral
loads per genotype were examined for HIV-positive and HIV-negative women.
The main 3 glycoprotein O (gO) genotypes (gO1a, gO1b, and gO5) were plot-
ted, and all the remaining genotypes were grouped together. All genotypes ap-
pear increased in HIV-positive women compared with HIV-negative women.
Genotype gO1a (black circle), gO1b (gray circle), gO5 (white circle), other
gO genotypes (crossed circle) are shown. Mean values are as follows:
2.6 × 105 and 5.9 × 104 for HIV-positive and HIV-negative women at both max-
imal and minimal secreted levels, at 4 and 16 weeks postpartum. Abbreviation:
DNA, deoxyribonucleic acid.
Table 1. Effects Maternal HIV and Breastfeeding Duration on
HCMV Infection
HCMV Infant Infection (Antibody)
Months
Breastfeeding
Antibody
N (%)
Adjusted ORa
(95% CI) P Value
HIV-Negative Mothers
<12b 25/32 (78.1%) 1
12–17 128/161 (79.5%) 0.94 (0.35–2.53)
18+ 110/119 (92.4%) 2.69 (0.84–8.59) .03
HIV-Positive Mothers
Never 13/26 (50.0%) 1
<6 31/35 (88.6%) 6.83 (1.69–27.6)
6+ 42/44 (95.5%) 20.37 (3.71–111.7) <.001
Abbreviations: CI, confidence interval; HCMV, human cytomegalovirus; HIV,
human immunodeficiency virus; OR, odds ratio.
a Adjusted for socioeconomic status and maternal education.
b Only 3 HIV-negative mothers never breastfed and only 6 for <6 months.
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peak HCMV DNA levels at 4 weeks postpartum but dif-
ferences in shedding duration. More HIV-positive than
HIV-negative women had detectable HCMV secretion in
breast milk, with initial reactivated levels equal at day 3,
then raised from 2 to 16 weeks postpartum. Recent studies
show HCMV-susceptible CD14+ leukocytes increasing in
breast milk at this time [35]. Thus, in milk secreted from
HIV-positive women, there appears to be decreased immune
regulation or increased susceptible cells, possibly from im-
mune activation or inﬂammation. Studies in this cohort
showed increased mastitis in HIV-positive women [29],
and we have demonstrated increased secretion of HCMV.
We further show that, in addition to increased risk of
congenital infection from intrauterine HCMV infection
[21-23], infants of HIV-infected women have increased
odds of HCMV infant infection from breastfeeding. This
can be a confounder for determining congenital infection,
because diagnostic tests by saliva in those under 2 weeks
of age may detect HCMV in saliva from breast milk. Our
studies of birth prevalence of HCMV in Zambia using new-
born saliva show 1% (1 of 100) prevalence in normal labor
ward (K.G.M. and U.A.G, unpublished), lower than studies
in the neonatal intensive care unit where breast milk could
also be a source of early infection [25].
Low socioeconomic status and level of education were
associated with HCMV seroprevalence in analyses of risk
factors, similar to those reported elsewhere [17, 36]. With
adjustment for these risk factors, breastfeeding up to 18
months remained signiﬁcantly associated with HCMV in-
fection. Studies in other continents show that almost all
HCMV-positive women excrete HCMV in breast milk
from local tissue reactivation, which is distinct from
detection in plasma. Even with breast milk secretion in
HCMV-positive mothers, the transmission rate varies,
and 58%–80% infants were found to be seropositive by
1 year of age [26]. In Europe and Asia, studies have
shown breast milk HCMV secretion up to 2–3 months
postpartum, with higher milk viral loads and prolonged
secretion linked to infant transmission [3, 28, 37]. In
Zambia, we showed sustained breast milk HCMV secre-
tion for over 4 months. Furthermore, increased breastfeed-
ing over 6 months among HIV-positive women, or over 18
months among HIV-negative women, increased risk of in-
fant HCMV infection. This shows that HCMV is secreted
(or possibly more transmissible in breast milk) for longer
duration than that reported in Europe or Asia. In
HIV-negative women, longer duration of lactation may in-
crease HCMV local reactivation and secretion. In
HIV-positive women, secreted levels may be further raised
through both HIV and HCMV immune dysregulation and
ampliﬁed with breastfeeding duration.
Increased transmission during breastfeeding also allows
for reinfections with multiple strains and widens the total
population exposure to HCMV infection. We previously
showed complex mixtures of HCMV strains, a potential
factor for severe HCMV disease (currently under assess-
ment) and a marker for burden of infection in this popula-
tion, from blood or lung samples of HIV-positive infants
[32].We used gO for genotyping, one of the most variable
genes in HCMV. Our genotype analyses showed that all 8
gO genotypes were detected in breast milk, demonstrating
that genotypes were not constrained in this tissue compart-
ment. There was also evidence for mixed-infections in-
dicative of reinfection, which was conﬁrmed using gN
genotyping (data not shown). In HIV-positive women,
viral load seemed to be raised independent of the genotypes
secreted. The main milk gO genotypes 1a, 1b, and 5 were
similar to prevalences we previously described in blood
and respiratory compartments of primarily HIV-infected
children in the same region and in other tissues from dif-
ferent global sources; differences in minor genotypes
did not reach signiﬁcance, although gO3 was greater in
other tissues (Supplementary Table 1 and Supplementary
Figure S1) [32, 33]. The analyses were limited by the
small proportion of samples available for genotype analy-
ses. These genotype ratios require further study, because
the gO trimeric or alternate pentameric complexes with
gH/gL glycoproteins affect host transmission and candi-
date vaccines [38, 39].
In the infant cohort, almost all HIV-negative women
breastfed their infants, whereas a quarter of HIV-positive
women never breastfed their infants, and overall HIV-
positive women had signiﬁcantly shorter breastfeeding du-
rations than HIV-negative women (median 6 months vs 15
months, P < .01). Various reasons, including trying to limit
infant HIV, were presented by the mothers [31]. This may
have provided some protection from HCMV infection to
children of HIV-positive mothers because those who
never breastfed were only 50% HCMV positive, whereas
breastfeeding at least to 6 months increased the prevalence
of HCMV-positive children to 88.6% and over 6 months
up to 95.5%. These differences in breastfeeding behavior
between HIV-positive and HIV-negative women also
meant that comparisons could only bemade using different
infant breastfeeding duration categories and are a limita-
tion of the study. The 6-fold and 20-fold increase in odds
of infection in adjusted analyses with breastfeeding to 6
months and over 6 months age, respectively, is in agree-
ment with the viral loads measured in breast milk.
Although limited from 2 different cohort studies, these were
from the same residential area and study clinic. A study in
Kenya showed that HCMV transmitters had a median of
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5.4 compared with 4.5 logs copies/mL in milk for nontrans-
mitters at 2 weeks postpartum [27]. Although it is difﬁcult to
apply exact thresholds, at similar times postpartum, in our
Zambian cohort, HIV-positive compared with negative
women had a median of 5.1 versus 4.0 logs copies/mL in
breast milk. Furthermore, between day 3 and week 16,
HIV-positive women had 23 measurements above 5.5 logs
copies/mL compared with only 7 for HIV-negative women.
This would indicate clinical relevance for the log differences
in HCMV milk secretion of increased risk for transmission
and at earlier times in the HIV-positive group.
In a separate analysis, we showed that HCMV adversely
affected this infant cohort’s growth and psychomotor
development, particularly in maternally HIV-exposed chil-
dren [17]. In Kenya, HCMV DNA in maternal plasma is a
predictor of mortality in HIV-infected women and their in-
fants [14],and lower CD4 levels were related to lower levels
of milk HCMV required for transmission [27]. Although it
was not measured, HCMV could be a factor in studies in
Zambia where women with advanced HIV/AIDS who
breastfed less than 4 months had improved infant survival
[42]. In Zimbabwe, HIV-positive women with HCMV co-
infection excreted both pathogens in breast milk, and
HCMV infection correlated with higher levels of HIV ribo-
nucleic acid [43].Further analyses showHCMVmilk secre-
tion in HIV-positive mothers correlates with infant
growth-faltering [18]. In United States, studies assessing
earlier ART during pregnancy in HIV-positive women
showed reductions in peri- or postnatal HCMV infection
[44]. Although this was a non-breastfeeding population,
the results support use of interventions to improve mater-
nal health, such as earlier use of ART in HIV-positive
women, which is now being applied in Zambia.
However, recent studies in African breastfed populations
showed that the use of antiretrovirals in HIV-positive
mothers did not restrict HCMV transmission to their in-
fants and therefore remained a risk for increasing numbers
of HIV-exposed uninfected children [16, 18].
There are several limitations to our studies. The HCMV
serostatus of the mothers was not known, although breast
milk DNA PCR showed that all mothers were HCMV pos-
itive. We did not have CD4 levels, and these can affect milk
secretion of CMV, as shown in studies of only HIV-positive
mothers in Kenya [27], and may have contributed to vary-
ing HCMV levels in the HIV-positive mothers. We did not
include day care status as a possible source for infant trans-
mission via saliva [40]; however, in Zambia, infant day
care is minimal to nonexistent. Other HCMV secretory
routes, particularly saliva and also urinary [41] from sib-
lings, can affect transmission, and 50% of infants became
HCMV seropositive from HIV-positive women who did
not breastfeed. However, we could not compare this result
to HIV-negative mothers because almost all of them
breastfed. Furthermore, most of our cohort mothers had
children under age 5 who could be secreting HCMV; there-
fore, in general, background exposure was equal. We did
not screen for prenatal HCMV, but this result would be
only approximately 1% based on previous studies on new-
borns. The strengths of this study are the size of the cohorts
and the comparison between both HIV-negative and HIV-
positive groups, which clearly show raised levels of HCMV
milk secretion and duration, with increased risks for infant
infection in HIV-positive compared with HIV-negative
women.
The World Health Organization recommends 6 months
exclusive breastfeeding for ideal infant nutrition and
immune protection. In Zambia, Demographic Health
Survey data show that 73% of infants are exclusively
breastfed for 6 months, and, overall, 98% of children
breastfed with a median duration of 20.1 months [45].
Possible interventions against HCMV need to retain
breastfeeding beneﬁts. Direct HCMV inactivation in milk
using ultrashort heat treatment has been evaluated in
Europe, particularly for at-risk, premature, and under-
weight infants, and was found to be effective while preserv-
ing the nutritional and immunological qualities of breast
milk [46]. This intervention warrants assessment in the
sub-Saharan Africa setting, where it could be useful for
concurrent inactivation of HCMV and HIV in breast
milk, for at risk groups. Administration of anti-HCMV
drugs to mothers to lower milk HCMV load is another po-
tential intervention, but this requires efﬁcacy and safety tri-
als; no anti-HCMV drug to date is licenced for use during
lactation. Improved hygiene could lower complementary
routes of transmission, including saliva or urine [47].
Furthermore, there are several promising vaccines currently
in development [48, 49].
CONCLUSIONS
We conclude that longer breastfeeding duration over 6 to
18 months increases HCMV infant infection. We also
showed that HIV-positive compared with HIV-negative
women had both raised breast milk secretion and likeli-
hood for infant infection. Interventions to reduce HCMV
infection could be considered, particularly in countries
with high HCMV andHIV prevalence, because breastfeed-
ing remains critical for infant health.
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